ArticleCancer prevention research (Philadelphia, Pa.)2011
Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis.
Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.Breast cancer research and treatment · 2024Pooled it
- The 2012 hormone therapy position statement of: The North American Menopause Society.Menopause (New York, N.Y.) · 2012Guideline
- Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.Journal of the National Cancer Institute · 2016Trial
- Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.JAMA oncology · 2015Trial
- Trial
- Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches.Cancers · 2023Review
- Cancer Prevention and Therapy of Two Types of Gap Junctional Intercellular Communication⁻Deficient "Cancer Stem Cell".Cancers · 2019Article
- Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models.British journal of cancer · 2018Article
- Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.Journal of women's health (2002) · 2018Article
- Article
- The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Molecular and cellular endocrinology · 2015Review
- Menopausal hormone therapy and breast cancer mortality: clinical implications.Therapeutic advances in drug safety · 2015Review
- Survivorship in untreated breast cancer patients.Medical oncology (Northwood, London, England) · 2015Review
- Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.SpringerPlus · 2015Article
- Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Journal of the National Cancer Institute · 2014Article
- Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.Steroids · 2014Review
- Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Diverse pathomechanisms leading to the breakdown of cellular estrogen surveillance and breast cancer development: new therapeutic strategies.Drug design, development and therapy · 2014Review
- Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications.OncoTargets and therapy · 2014Article
- Occult breast tumor reservoir: biological properties and clinical significance.Hormones & cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Administration of estrogen replacement therapy (ERT) decreases the incidence of breast cancer, as shown in a double-blind, placebo-controlled randomized trial of the Women's Health Initiative (WHI) in 10,739 postmenopausal women with a prior hysterectomy. Although paradoxical because estrogen is recognized to stimulate breast cancer growth, laboratory data support a mechanism of estrogen-induced apoptosis under the correct environmental circumstances. Long-term antiestrogen treatment or estrogen deprivation causes the eventual development and evolution of antihormone resistance. Cell populations emerge with a vulnerability, as estrogen is no longer a survival signal but is an apoptotic trigger. The antitumor effect of ERT in estrogen-deprived postmenopausal women is consistent with laboratory models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.